Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Mei Qiu; Liang-Liang Ding; Ze-Lin Zhan; Hai-Rong Zhou

doi:10.3389/fendo.2021.664502

Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Front Endocrinol (Lausanne). 2021 Mar 26:12:664502. doi: 10.3389/fendo.2021.664502. eCollection 2021.

Authors

Mei Qiu¹, Liang-Liang Ding², Ze-Lin Zhan³, Hai-Rong Zhou¹

Affiliations

¹ Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China.
² Department of Endocrinology, First Affiliated Hospital of Yangtze University, Jingzhou, China.
³ Class 3, Clinical Medicine, Grade 2019, The Second Clinical Medical College, Southern Medical University, Guangzhou, China.

No abstract available

Keywords: SGLT2 inhibitors (gliflozins); all-cause death; cardiovascular death; heart failure - pharmacological treatment - systolic dysfunction; type 2 diabetes (clinical domain).

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Heart Failure* / drug therapy
Heart Failure* / epidemiology
Heart Failure* / prevention & control
Hospitalization
Humans
Randomized Controlled Trials as Topic
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors